Białko mitochondrialne CMPK2 reguluje tworzenie
Białko mitochondrialne CMPK2 reguluje tworzenie komórek piankowatych wzmocnionych przez IFN alfa, potencjalnie przyczyniając się do przedwczesnej miażdżycy tętnic w SLE
Background: Untimely atherosclerosis happens in sufferers with SLE; nonetheless, the mechanisms stay unclear. Each mitochondrial equipment and proinflammatory cytokine interferon alpha (IFN-α) probably contribute to atherogenic processes in SLE. Right here, we discover the roles of the mitochondrial protein cytidine/uridine monophosphate kinase 2 (CMPK2) in IFN-α-mediated pro-atherogenic occasions.
Strategies: Foam cell measurements have been carried out by oil purple O staining, Dil-oxLDL uptake and the BODIPY strategy. The mRNA and protein ranges have been measured by qPCR and Western blotting, respectively. Isolation of CD4+ T cells and monocytes was carried out with monoclonal antibodies conjugated with microbeads. Manipulation of protein expression was performed by both small interference RNA (siRNA) knockdown or CRISPR/Cas9 knockout. The expression of mitochondrial reactive oxygen species (mtROS) was decided by circulate cytometry and confocal microscopy.
Outcomes: IFN-α enhanced oxLDL-induced foam cell formation and Dil-oxLDL uptake by macrophages. Along with IFN-α, a number of triggers of atherosclerosis, together with thrombin and IFN-γ, can induce CMPK2 expression, which was elevated in CD4+ T cells and CD14+ monocytes remoted from SLE sufferers in comparison with these remoted from controls. The evaluation of mobile subfractions revealed that CMPK2 was current in each mitochondrial and cytosolic fractions. IFN-α-induced CMPK2 expression was inhibited by Janus kinase (JAK)half of and tyrosine kinase 2 (Tyk2) inhibitors. Each the knockdown and knockout of CMPK2 attenuated IFN-α-mediated foam cell formation, which concerned the discount of scavenger receptor class A (SR-A) expression. CMPK2 additionally regulated IFN-α-enhanced mtROS manufacturing and inflammasome activation.
Conclusions: The research means that CMPK2 performs contributing roles within the pro-atherogenic results of IFN-α.
Human Tubulin beta- 4 chain, TUBB4 ELISA KIT |
|||
| ELI-13731h | Lifescience Market | 96 Tests | EUR 988.8 |
Donkey anti Goat IgG (H + L) (Alexa Fluor 594) |
|||
| 43R-ID005AF | Fitzgerald | 500 ug | EUR 405.6 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|||
Donkey anti Rat IgG (H + L) (Alexa Fluor 594) |
|||
| 43R-ID022AF | Fitzgerald | 500 ug | EUR 436.8 |
|
Description: Donkey anti Rat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|||
Donkey anti Rat IgG (H + L) (Alexa Fluor 594) |
|||
| 43R-ID047AF | Fitzgerald | 500 ug | EUR 554.4 |
|
Description: Donkey anti Rat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|||
Donkey anti Chicken IgY (H + L) (Alexa Fluor 594) |
|||
| 43R-ID056AF | Fitzgerald | 500 ug | EUR 411.6 |
|
Description: Donkey anti Chicken IgY secondary antibody (H + L) (Alexa Fluor 594) |
|||
Rabbit anti Chicken IgY (H + L) (Alexa Fluor 594) |
|||
| 43R-IR016AF | Fitzgerald | 1 mg | EUR 337.2 |
|
Description: Rabbit anti Chicken IgY (H + L) secondary antibody (Alexa Fluor 594) |
|||
XFD594 Anti-human CD32 Antibody *IV.3, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10320170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD32 Antibody *IV.3, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10320171 | AAT Bioquest | 500 tests | EUR 918 |
ELISA kit for Human Tubulin beta-4 chain (TUBB4) |
|||
| KTE60116-48T | Abbkine | 48T | EUR 398.4 |
|
Description: Quantitative sandwich ELISA for measuring Human Tubulin beta-4 chain (TUBB4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
|||
ELISA kit for Human Tubulin beta-4 chain (TUBB4) |
|||
| KTE60116-5platesof96wells | Abbkine | 5 plates of 96 wells | EUR 2538 |
|
Description: Quantitative sandwich ELISA for measuring Human Tubulin beta-4 chain (TUBB4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
|||
ELISA kit for Human Tubulin beta-4 chain (TUBB4) |
|||
| KTE60116-96T | Abbkine | 96T | EUR 646.8 |
|
Description: Quantitative sandwich ELISA for measuring Human Tubulin beta-4 chain (TUBB4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
|||
iFluor® 594 Styramide *Superior Replacement for Alexa Fluor 594 tyramide* |
|||
| 45035 | AAT Bioquest | 100 Slides | EUR 334 |
Anti-gamma-Tubulin Alexa Fluor647 |
|||
| A6-465-C025 | ExBio | 0.025 mg | EUR 260.4 |
Anti-gamma-Tubulin Alexa Fluor647 |
|||
| A6-465-C100 | ExBio | 0.1 mg | EUR 472.8 |
Donkey anti Goat IgG (H + L) (Fab 2) (Alexa Fluor 594) |
|||
| 43R-ID012AF | Fitzgerald | 300 ug | EUR 492 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Fab'2) (Alexa Fluor 594) |
|||
Donkey Anti-Goat IgG (H+L), Alexa Fluor® 594 Conjugated |
|||
| Ab8011-001 | GenDepot | 1mg | EUR 400.8 |
AF594-streptavidin conjugate [Streptavidin, Alexa Fluor™ 594 Conjugate] |
|||
| 16892 | AAT Bioquest | 1 mg | EUR 211.2 |
AF594 Phalloidin [equivalent to Alexa Fluor® 594 phalloidin] |
|||
| 23158 | AAT Bioquest | 300 Tests | EUR 367.2 |
Anti-beta-Tubulin Purified |
|||
| 11-251-C025 | ExBio | 0.025 mg | EUR 135.6 |
Anti-beta-Tubulin Purified |
|||
| 11-251-C100 | ExBio | 0.1 mg | EUR 223.2 |
Anti-beta-Tubulin Purified |
|||
| 11-427-C025 | ExBio | 0.025 mg | EUR 135.6 |
Anti-beta-Tubulin Purified |
|||
| 11-427-C100 | ExBio | 0.1 mg | EUR 223.2 |
Anti-beta-Tubulin Purified |
|||
| 11-444-C025 | ExBio | 0.025 mg | EUR 135.6 |
Anti-beta-Tubulin Purified |
|||
| 11-444-C100 | ExBio | 0.1 mg | EUR 223.2 |
Anti-beta Tubulin antibody |
|||
| PAab00879 | Lifescience Market | 100 ug | EUR 463.2 |
Anti-Beta Tubulin antibody |
|||
| PAab00880 | Lifescience Market | 100 ug | EUR 463.2 |
anti- Beta Tubulin antibody |
|||
| LSMab09872 | Lifescience Market | 100 ug | EUR 463.2 |
anti-beta-Tubulin (5G3) |
|||
| LF-MA20322 | Abfrontier | 100 ug | EUR 400.8 |
|
Description: Mouse monoclonal to betA tubulin |
|||
anti-beta-tubulin (M6) |
|||
| LF-MA20425 | Abfrontier | 100 ug | EUR 400.8 |
|
Description: Mouse monoclonal to Beta tubulin |
|||
anti-beta II tubulin |
|||
| LF-MA20432 | Abfrontier | 100 ug | EUR 400.8 |
|
Description: Mouse monoclonal to beta II tubulin |
|||
anti- beta Tubulin antibody |
|||
| FNab00879 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against beta Tubulin |
|||
anti- Beta Tubulin antibody |
|||
| FNab00880 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against Beta Tubulin |
|||
anti- Tubulin-beta antibody |
|||
| FNab09105 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against Tubulin-beta |
|||
anti- Beta Tubulin antibody |
|||
| FNab09872 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against Beta Tubulin |
|||
Anti-Tubulin beta antibody |
|||
| STJ98436 | St John's Laboratory | 100 µl | EUR 280.8 |
|
Description: Mouse monoclonal to Tubulin beta. |
|||
Anti-Tubulin beta antibody |
|||
| STJ98566 | St John's Laboratory | 100 µl | EUR 280.8 |
|
Description: Mouse monoclonal to Tubulin beta. |
|||
Anti-beta-Tubulin antibody |
|||
| STJ99132 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to beta-Tubulin. |
|||
Anti-beta-Tubulin antibody |
|||
| STJ99133 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to beta-Tubulin. |
|||
Anti-Tubulin beta antibody |
|||
| STJ96145 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Beta tubulin is a protein encoded by the tubb gene which is approximately 49,7 kDa. Beta tubulin is localised to the cytoskeleton and cytoplasm. It is involved in the regulation of PLK1 activity at G2/M transition, development of Slit-Robo signalling, the innate immune system, cell cycle and organelle biogenesis and maintenance. Beta tubulin contains a highly acidic C-terminal region which can bind cations such as calcium. Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain and forms part of the cytoskeleton. Beta tubulin is ubiquitously expressed in the spleen, thymus and immature brain. Mutations in the tubb gene result in complex cortical dysplasia with other brain malformations. Mutations can also cause congenital symmetric circumferential, an autosomal dominant disease which results in multiple rings of folded skin mostly affecting the limbs. STJ96145 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of Tubulin beta protein. |
|||
Anti-beta-Tubulin antibody |
|||
| STJ96932 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Beta tubulin is a protein encoded by the tubb gene which is approximately 49,7 kDa. Beta tubulin is localised to the cytoskeleton and cytoplasm. It is involved in the regulation of PLK1 activity at G2/M transition, development of Slit-Robo signalling, the innate immune system, cell cycle and organelle biogenesis and maintenance. Beta tubulin contains a highly acidic C-terminal region which can bind cations such as calcium. Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain and forms part of the cytoskeleton. Beta tubulin is ubiquitously expressed in the spleen, thymus and immature brain. Mutations in the tubb gene result in complex cortical dysplasia with other brain malformations. Mutations can also cause congenital symmetric circumferential, an autosomal dominant disease which results in multiple rings of folded skin mostly affecting the limbs. STJ96932 was developed from clone 1E1-E8-H4 and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody detects endogenous beta tubulin. |
|||
Anti-beta-Tubulin antibody |
|||
| STJ97016 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to beta-Tubulin. |
|||
Anti-beta-tubulin antibody |
|||
| STJ97037 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Beta tubulin is a protein encoded by the tubb gene which is approximately 49,7 kDa. Beta tubulin is localised to the cytoskeleton and cytoplasm. It is involved in the regulation of PLK1 activity at G2/M transition, development of Slit-Robo signalling, the innate immune system, cell cycle and organelle biogenesis and maintenance. Beta tubulin contains a highly acidic C-terminal region which can bind cations such as calcium. Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain and forms part of the cytoskeleton. Beta tubulin is ubiquitously expressed in the spleen, thymus and immature brain. Mutations in the tubb gene result in complex cortical dysplasia with other brain malformations. Mutations can also cause congenital symmetric circumferential, an autosomal dominant disease which results in multiple rings of folded skin mostly affecting the limbs. STJ97037 was developed from clone M7. The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. The antibody detects endogenous beta tubulin. |
|||
Anti-beta-tubulin antibody |
|||
| STJ97041 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to beta-tubulin. |
|||
Anti-beta Tubulin antibody |
|||
| STJ97131 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to beta Tubulin. |
|||
Anti-Tubulin Beta antibody |
|||
| STJ31562 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Unonjugated rabbit polyclonal to tubulin beta |
|||
Anti-beta Tubulin antibody |
|||
| STJ13100428 | St John's Laboratory | 150 µl | EUR 512.4 |
Anti-Tubulin beta antibody |
|||
| STJ13100435 | St John's Laboratory | 500 µg | EUR 512.4 |
Anti-Beta-Tubulin antibody |
|||
| STJ16100474 | St John's Laboratory | 100 µg | EUR 487.2 |
anti-beta II Tubulin |
|||
| YF-PA23016 | Abfrontier | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal to beta II Tubulin |
|||
anti-beta II Tubulin |
|||
| YF-PA25563 | Abfrontier | 50 ul | EUR 400.8 |
|
Description: Mouse polyclonal to beta II Tubulin |
|||
Anti-Beta-tubulin Antibody |
|||
| A1216-100 | Biovision | each | EUR 483.6 |
Human Kinase Library IV |
|||
| HKIN-IV | Real Time Primers | 1 set | EUR 540 |
alpha Tubulin (alpha Tubulin) Antibody (ATTO 594) |
|||
| abx446844-100ug | Abbexa | 100 ug | EUR 693.6 |
Recombinant (E.Coli) Human Thyrostimulin Beta |
|||
| RP-594 | Alpha Diagnostics | 10 ug | EUR 343.2 |
Beta-Tubulin |
|||
| MO22180 | Neuromics | 100 ug | EUR 522 |
Anti-RPSA Alexa Fluor® 488 |
|||
| A4-829-C100 | ExBio | 0.1 mg | EUR 372 |
Anti-CD40 antibody (Alexa-fluor 488) |
|||
| STJ170000 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: CD40 (48 to 50 kDa) is a transmembrane glycoprotein mainly expressed on the surface of B cells and also expressed on monocytes, dendritic cells, and thymic epithelium. CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the low affinity nerve growth factor (NGF) receptor and CD95/Fas. CD40 is the receptor for CD40 ligand. CD40L (CD40L, CD154, gp39, and TRAM) belongs to the TNF gene family and is expressed more widely than CD40, predominantly on activated CD4+ T cells. Following interaction with CD40 ligand, CD40 mediates a number of major immunoregulatory functions, central to the control of thymus dependent humoral immunity and may be critical in the development of cell mediated immune responses. Other biological actions include B cell homotypic adhesion, proliferation, immunoglobulin isotype switch, and secretion. Activation of CD40 has also been shown to inhibit the growth of certain B cell lymphomas and to induce the death of transformed cells of mesenchymal or epithelial origin |
|||
Anti-LAMP3 antibody (Alexa-fluor 488) |
|||
| STJ170004 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
|||
Anti-LAMP3 antibody (Alexa-fluor 546) |
|||
| STJ170005 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
|||
Anti-LAMP3 antibody (Alexa-fluor 647) |
|||
| STJ170006 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
|||
Anti-IL3RA antibody (Alexa-fluor 488) |
|||
| STJ170009 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
Anti-IL3RA antibody (Alexa-fluor 546) |
|||
| STJ170010 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
Anti-IL3RA antibody (Alexa-fluor 647) |
|||
| STJ170011 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
Anti-CD207 antibody (Alexa-fluor 488) |
|||
| STJ170014 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
Anti-CD207 antibody (Alexa-fluor 546) |
|||
| STJ170015 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
Anti-CD207 antibody (Alexa-fluor 647) |
|||
| STJ170016 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
Anti-IL7R antibody (Alexa-fluor 488) |
|||
| STJ170020 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
Anti-IL7R antibody (Alexa-fluor 546) |
|||
| STJ170021 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
Anti-IL7R antibody (Alexa-fluor 647) |
|||
| STJ170022 | St John's Laboratory | 100 µg | EUR 471.6 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
Anti-Beta Tubulin/TUBB Antibody |
|||
| A01857-1 | BosterBio | 100ug/vial | EUR 400.8 |
Anti- Beta-tubulin Monoclonal Antibody |
|||
| M05613-2 | BosterBio | 100ul | EUR 476.4 |
|
Description: Mouse Monoclonal Beta-tubulin Antibody. Validated in IF, IHC, WB and tested in Human, Monkey, Mouse, Rat. |
|||
Anti- Beta-tubulin Monoclonal Antibody |
|||
| M05613-3 | BosterBio | 100ul | EUR 476.4 |
|
Description: Mouse Monoclonal Beta-tubulin Antibody. Validated in IHC, WB and tested in Human, Monkey, Mouse, Rat. |
|||
anti-beta I tubulin (3F7) |
|||
| LF-MA20329 | Abfrontier | 100 ug | EUR 400.8 |
|
Description: Mouse monoclonal to beta I tubulin |
|||
Anti-beta I tubulin antibody |
|||
| STJ96939 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: beta I tubulin is a protein encoded by the TUBB1 gene which is approximately 50,3 kDa. beta I tubulin is localised to the cytoplasm. It is involved in development Slit-Robo signalling, Sertoli-Sertoli cell junction dynamics, signalling in gap junctions and chaperonin-mediated protein folding. This protein falls under the beta tubulin protein family. It is one of two core protein families that heterodimerize and assemble to form microtubules. It is exists in platelets and megakaryocytes and may be involved in proplatelet production and platelet release. beta I tubulin is expressed in the blood and cells of the nervous system. Mutations in the TUBB1 gene may result in macrothrombocytopaenia. STJ96939 was developed from clone 3F7 and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody detects endogenous beta I tubulin proteins. |
|||
Anti-beta I tubulin antibody |
|||
| STJ97021 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to beta I tubulin. |
|||
Anti-beta II tubulin antibody |
|||
| STJ97053 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: beta II tubulin is a protein encoded by the TUBB2A gene which is approximately 49,9 kDa. beta II tubulin is localised to the cytoplasm and cytoskeleton. It is involved in Sertoli-Sertoli cell junction dynamics, development Slit-Robo signalling and the GPCR pathway. Tubulin is the major constituent of microtubules. Microtubules are key participants in processes such as mitosis and intracellular transport and are composed of heterodimers of alpha- and beta-tubulins. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. beta II tubulin is expressed in the nervous system, eye, skin and lung. Mutations in the TUBB2A gene may result in lung mucoepidermoid carcinoma. STJ97053 was developed from clone Mix and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. The antibody detects endogenous beta II tubulin protein. |
|||
Anti-beta III tubulin antibody |
|||
| STJ97067 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to beta III tubulin. |
|||
Anti-beta II Tubulin antibody |
|||
| STJ97122 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to beta II Tubulin. |
|||
Anti-beta III Tubulin antibody |
|||
| STJ97123 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Beta III tubulin is a protein encoded by the tubb3 gene which is approximately 50,4 kDa. Beta III tubulin is localised to the cytoplasm and cytoskeleton. It is involved in signalling within gap junctions, development slit-robo signalling, sertoli-sertoli cell junction dynamics, chaperonin-mediated protein folding and tubulin folding. This protein falls under the one of two protein families, namely beta and alpha tubulin and is one of six beta tubulin isoforms. Beta III tubulin is expressed in the neurons of the peripheral and central nervous system and plays an important role in guidance and maintenance and axons. Mutations in the tubb3 gene result in congenital fibrosis of extraocular muscles type. STJ97123 was developed from clone Mix. It was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. The antibody detects endogenous beta III tubulin protein. |
|||
Anti-beta-tubulin antibody (HRP) |
|||
| STJ97477 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Beta tubulin is a protein encoded by the tubb gene which is approximately 49,7 kDa. Beta tubulin is localised to the cytoskeleton and cytoplasm. It is involved in the regulation of PLK1 activity at G2/M transition, development of Slit-Robo signalling, the innate immune system, cell cycle and organelle biogenesis and maintenance. Beta tubulin contains a highly acidic C-terminal region which can bind cations such as calcium. Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain and forms part of the cytoskeleton. Beta tubulin is ubiquitously expressed in the spleen, thymus and immature brain. Mutations in the tubb gene result in complex cortical dysplasia with other brain malformations. Mutations can also cause congenital symmetric circumferential, an autosomal dominant disease which results in multiple rings of folded skin mostly affecting the limbs. STJ97477 was developed from clone 5G3. The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. The antibody detects endogenous beta tubulin (HRP Conjugated). |
|||
Anti-Tubulin, beta III antibody |
|||
| STJ120262 | St John's Laboratory | 100 µl | EUR 631.2 |
Anti-Beta III Tubulin antibody |
|||
| STJ16100477 | St John's Laboratory | 100 µg | EUR 487.2 |
Anti-beta II Tubulin (1F9) |
|||
| YF-MA17277 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to beta II Tubulin |
|||
Anti-beta II Tubulin (1G3) |
|||
| YF-MA17278 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to beta II Tubulin |
|||
alpha Tubulin (alpha Tubulin) Antibody (PE/ATTO 594) |
|||
| abx446854-100ug | Abbexa | 100 ug | EUR 710.4 |
XFD594 tyramide reagent *Same Structure to Alexa Fluor™ 594 tyramide* |
|||
| 11082 | AAT Bioquest | 200 slides | EUR 222 |
Rabbit Anti-Rat IgG (H+L)-Alexa 594 Fluor conjugate (adsorbed with human IgG) |
|||
| 50337 | Alpha Diagnostics | 0.5 ml | EUR 270 |
XFD594 Anti-human CD47 Antibody *HI172, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10471170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD47 Antibody *HI172, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10471171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD52 Antibody *HI186, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10520170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD52 Antibody *HI186, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10520171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD53 Antibody *HI29, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10530170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD53 Antibody *HI29, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10530171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD53 Antibody *HI36, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10531170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD53 Antibody *HI36, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10531171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD55 Antibody *HI55a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10550170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD55 Antibody *HI55a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10550171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD56 Antibody *My31, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10562160 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD56 Antibody *My31, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10562161 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD57 Antibody *HI57a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10570170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD57 Antibody *HI57a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10570171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD58 Antibody *HI58a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10580170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD58 Antibody *HI58a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10580171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD62 Antibody *HI62E, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10620170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD62 Antibody *HI62E, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10620171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD62l Antibody *HI62L, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10621170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD62l Antibody *HI62L, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10621171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD62p Antibody *HI62P, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10622170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD62p Antibody *HI62P, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10622171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD64 Antibody *10.1, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10640170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD64 Antibody *10.1, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10640171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD69 Antibody *FN50, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10690170 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD69 Antibody *FN50, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10690171 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD71 Antibody *HI160, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10710170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD71 Antibody *HI160, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10710171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD71 Antibody *HI166, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10711170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD71 Antibody *HI166, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10711171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD72 Antibody *3F3, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10720170 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD72 Antibody *3F3, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10720171 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD73 Antibody *AD2, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10730170 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD73 Antibody *AD2, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10730171 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD5 Antibody *HISM2, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10050170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD5 Antibody *HISM2, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10050171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD5 Antibody *L17F12, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10051170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD5 Antibody *L17F12, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10051171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD5 Antibody *UCHT2, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10052170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD5 Antibody *UCHT2, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10052171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD6 Antibody *HI210, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10060170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD6 Antibody *HI210, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10060171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD7 Antibody *HIT7, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10070170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD7 Antibody *HIT7, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10070171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD8 Antibody *HIT8a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10080170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD8 Antibody *HIT8a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10080171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD8 Antibody *SK1, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10081170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD8 Antibody *SK1, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10081171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD9 Antibody *HI9a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10090170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD9 Antibody *HI9a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10090171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD10 Antibody *HI10a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10100170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD10 Antibody *HI10a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10100171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD11a Antibody *HI111, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10110170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD11a Antibody *HI111, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10110171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD11b Antibody *HI11b, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10111170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD11b Antibody *HI11b, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10111171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD11b Antibody *ICRF44, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10112170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD11b Antibody *ICRF44, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10112171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD11c Antibody *3.9, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10113170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD11c Antibody *3.9, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10113171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD13 Antibody *WM15, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10130170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD13 Antibody *WM15, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10130171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD14 Antibody *61D3, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10141170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD14 Antibody *61D3, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10141171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD15 Antibody *HI98, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10150170 | AAT Bioquest | 100 tests | EUR 296 |
XFD594 Anti-human CD15 Antibody *HI98, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10150171 | AAT Bioquest | 500 tests | EUR 1020 |
XFD594 Anti-human CD16 Antibody *HI16a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10160170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD16 Antibody *HI16a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10160171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD16 Antibody *3G8, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10161170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD16 Antibody *3G8, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10161171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD18 Antibody *HI18a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10180170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD18 Antibody *HI18a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10180171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD19 Antibody *HI19a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10190170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD19 Antibody *HI19a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10190171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD19 Antibody *SJ25C1, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10191170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD19 Antibody *SJ25C1, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10191171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD19 Antibody *HIB19, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10192170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD19 Antibody *HIB19, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10192171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD19 Antibody *4G7, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10193170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD19 Antibody *4G7, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10193171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-mouse CD19 Antibody *1D3, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10194160 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-mouse CD19 Antibody *1D3, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10194161 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD20 Antibody *HI20a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10201170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD20 Antibody *HI20a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10201171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD21 Antibody *HI21a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10210170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD21 Antibody *HI21a, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10210171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD22 Antibody *HIB22, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10220170 | AAT Bioquest | 100 tests | EUR 245 |
XFD594 Anti-human CD22 Antibody *HIB22, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 10220171 | AAT Bioquest | 500 tests | EUR 918 |
XFD594 Anti-human CD101 Antibody *BB27, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11010160 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD101 Antibody *BB27, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11010161 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD107 Antibody *H4B4, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11071160 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD107 Antibody *H4B4, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11071161 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD109 Antibody *W7C5, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11090160 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD109 Antibody *W7C5, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11090161 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD111 Antibody *R1.302, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11110160 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD111 Antibody *R1.302, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11110161 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD112 Antibody *R2.525, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11120160 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD112 Antibody *R2.525, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11120161 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD114 Antibody *LMM741, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11140160 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD114 Antibody *LMM741, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11140161 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD116 Antibody *4H1, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11160160 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD116 Antibody *4H1, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11160161 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD117 Antibody *104D2, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11170170 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD117 Antibody *104D2, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11170171 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD120a Antibody *H398, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11200160 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD120a Antibody *H398, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11200161 | AAT Bioquest | 500 tests | EUR 2051 |
XFD594 Anti-human CD122 Antibody *TU27, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11220160 | AAT Bioquest | 100 tests | EUR 547 |
XFD594 Anti-human CD122 Antibody *TU27, XFD594 Same Structure to Alexa Fluor™ 594* |
|||
| 11220161 | AAT Bioquest | 500 tests | EUR 2051 |
Ocena odpowiedzi immunogennej na nowatorską szczepionkę z koniugatem enterobaktyny u kurcząt do produkcji przeciwciał żółtka jaja specyficznych dla enterobaktyny
- Passive immunization with particular egg yolk antibodies (immunoglobulin Y, IgY) is rising as a promising various to antibiotics to manage bacterial infections. Lately, we developed a novel conjugate vaccine that might set off a robust immune response in rabbits directed towards enterobactin (Ent), a extremely conserved siderophore molecule utilized by completely different Gram-negative pathogens. Nevertheless, induction of Ent-specific antibodies seemed to be affected by the selection of animal host and vaccination routine.
- It’s nonetheless unknown if the Ent conjugate vaccine can set off a selected immune response in layers for the aim of manufacturing of anti-Ent egg yolk IgY. On this research, three hen vaccination trials with completely different regimens have been carried out to find out circumstances for environment friendly manufacturing of anti-Ent egg yolk IgY. Purified Ent was conjugated to 3 provider proteins, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) and CmeC (a subunit vaccine candidate), respectively.
- Intramuscular immunization of Barred Rock layers with KLH-Ent conjugate 4 instances induced sturdy immune response towards entire conjugate vaccine however the titer of Ent-specific IgY didn’t change in yolk with solely a four fold improve detected in serum. Within the second trial, three completely different Ent conjugate vaccines have been evaluated in Rhode Island Crimson pullets with 4 subcutaneous injections. The KLH-Ent or CmeC-Ent conjugate persistently induced excessive degree of Ent-specific IgY in each serum (as much as 2,048 fold) and yolk (as much as 1,024 fold) in every particular person hen. Nevertheless, the Ent-specific immune response was solely quickly and reasonably induced utilizing a BSA-Ent vaccination.
- Within the third trial, ten White Leghorn layers have been subcutaneously immunized thrice with KLH-Ent, resulting in constant and robust immune response towards each entire conjugate and the Ent molecule in every hen; the imply titer of Ent-specific IgY elevated roughly 32 and 256 fold in serum and yolk, respectively. According to its potent binding to numerous Ent derivatives, the Ent-specific egg yolk IgY additionally inhibited in vitro progress of a consultant Escherichia coli pressure.
- Collectively, this research demonstrated that the novel Ent conjugate vaccine might induce sturdy, particular, and sturdy immune response in chickens. The Ent-specific hyperimmune egg yolk IgY has potential for passive immune intervention towards Gram-negative infections.
Korelacja odpowiedzi na szczepionki
Introduction: The humoral response to vaccinations varies extensively between people. There isn’t a information obtainable on the correlation between responses to completely different vaccines. On this research, we investigated the correlation of antibody responses between routine vaccine antigens in infants.
Strategies: One and 7 months after the 6-month vaccinations and one month after the 12-month vaccinations, antibody concentrations to diphtheria, tetanus, pertussis, polio (serotypes 1-3), Haemophilus influenzae sort b (Hib), pneumococcus (13 serotypes), meningococcus C, measles, mumps and rubella have been measured utilizing fluorescent bead-based multiplex immune-assays. For the correlation of antibody responses, Spearman’s rank correlation coefficients (ρ) with 95% confidence intervals (CI) have been calculated between responses to every vaccine antigen.
Outcomes: The correlation between concentrations of antibodies to the vaccinations ending at 6 months of age was greater one month in comparison with seven months after vaccination. The strongest correlations at each time factors have been noticed between antibody responses to completely different polio serotypes, sure pneumococcal serotypes and between responses to diphtheria and pneumococcal (conjugated to a diphtheria toxoid) vaccine antigens. Correlation between responses to tetanus, Hib, pertussis, polio and different vaccine antigens have been weak. The correlation between antibody responses to the 12-month vaccine antigens was weaker than to the 6-month vaccine antigens and there was a adverse correlation between responses to measles, mumps, rubella vaccine and non-live vaccine antigens (meningococcus C, tetanus and Hib). There was solely weak correlation between antibody responses to vaccines of the identical sort (e.g. conjugated polysaccharide or toxoid vaccines).
Conclusion: Correlation between antibody responses to related antigens in the identical vaccine (equivalent to completely different serotypes of a micro organism or virus), in addition to responses to antigens conjugated to related provider proteins, are sturdy. In distinction, correlation between responses to different vaccines are weak. Measuring antibody responses to at least one or a number of vaccine antigens subsequently doesn’t supply a dependable surrogate marker of responses to unrelated vaccines.
Nowatorski automatyczny check immunologiczny dla przeciwciał NY-ESO-1 i XAGE1 w surowicy w skojarzonym przewidywaniu odpowiedzi na terapię przeciw zaprogramowanej śmierci komórkowej – 1 w niedrobnokomórkowym raku płuca
Background: Anti-programmed cell death-1 (PD-1) antibodies (Abs) are key medication in non-small-cell lung most cancers (NSCLC) remedy; nonetheless, medical advantages with anti-PD-1 monotherapy are restricted. We reported that serum Abs towards cancer-testis antigens NY-ESO-1 and XAGE1 predicted medical advantages. We aimed to develop a totally automated immunoassay system measuring NY-ESO-1/XAGE1 Abs.
Strategies: Sera from 30 NSCLC sufferers earlier than anti-PD-1 monotherapy have been reacted with recombinant NY-ESO-1 protein- or artificial XAGE1 peptide-coated magnetic beads. ALP-conjugated Ab and chemiluminescent substrate have been added and luminescence measured. These procedures have been automated utilizing excessive sensitivity chemiluminescent enzyme immunoassay (HISCLTM). NY-ESO-1/XAGE1 Ab stability was examined beneath numerous circumstances. Response prediction accuracy was evaluated utilizing space beneath receiver working curve (AUROC).
Outcomes: HISCL detected particular serum NY-ESO-1/XAGE1 Abs, which ranges in ELISA and HISCL have been extremely correlated. The Ab ranges in HISCL have been secure at 4 temperatures, 5 freeze/thaw cycles, and long-term storage; the degrees weren’t interfered by frequent blood elements. The Ab ranges in 15 NSCLC responders to anti-PD-1 monotherapy have been considerably greater than these in non-responders and wholesome donors. The AUROC was the best (0.91; 95% CI, 0.78-1.0) in combinatory prediction with NY-ESO-1/XAGE1 Abs.
Conclusion: Our immunoassay system is beneficial to foretell medical advantages with NSCLC immune-checkpoint remedy.
